Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Yoshinami T, Takano Y, Ozaki Y, Kajiwara Y, Yamamoto M, Watanabe KI, Tsukabe M, Fujisawa F, Nagai SE, Shibata N, Oshiro C, Bando H, Tsunoda N, Yamagami K, Koizumi K, Takada M, Toriguchi N, Sekine N, Kawaguchi T, Saji S, Sagara Y, Morita S, Masuda N.

Open source

DOI: 10.1007/s12282-025-01713-7
Published: 2025-05-20
Container: Breast Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12282-025-01713-7,
  title = {Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.},
  author = {Yoshinami T and  Takano Y and  Ozaki Y and  Kajiwara Y and  Yamamoto M and  Watanabe KI and  Tsukabe M and  Fujisawa F and  Nagai SE and  Shibata N and  Oshiro C and  Bando H and  Tsunoda N and  Yamagami K and  Koizumi K and  Takada M and  Toriguchi N and  Sekine N and  Kawaguchi T and  Saji S and  Sagara Y and  Morita S and  Masuda N.},
  year = {2025},
  journal = {Breast Cancer},
  doi = {10.1007/s12282-025-01713-7},
  url = {https://doi.org/10.1007/s12282-025-01713-7}
}

RIS

TY  - JOUR
TI  - Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
AU  - Yoshinami T
AU  -  Takano Y
AU  -  Ozaki Y
AU  -  Kajiwara Y
AU  -  Yamamoto M
AU  -  Watanabe KI
AU  -  Tsukabe M
AU  -  Fujisawa F
AU  -  Nagai SE
AU  -  Shibata N
AU  -  Oshiro C
AU  -  Bando H
AU  -  Tsunoda N
AU  -  Yamagami K
AU  -  Koizumi K
AU  -  Takada M
AU  -  Toriguchi N
AU  -  Sekine N
AU  -  Kawaguchi T
AU  -  Saji S
AU  -  Sagara Y
AU  -  Morita S
AU  -  Masuda N.
PY  - 2025
JO  - Breast Cancer
DO  - 10.1007/s12282-025-01713-7
UR  - https://doi.org/10.1007/s12282-025-01713-7
ER  -

APA

T, Y., Y, T., Y, O., Y, K., M, Y., KI, W., M, T., F, F., SE, N., N, S., C, O., H, B., N, T., K, Y., K, K., M, T., N, T., N, S., T, K., S, S., Y, S., S, M., & N., M. (2025). Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.. Breast Cancer. https://doi.org/10.1007/s12282-025-01713-7

Source records

europe-pmc · retrieved 2026-09-27T06:59:20.715Z